Effect of Solutol HS 15 in Solid Dispersions of Pioglitazone Hydrochloride: in vitro and in vivo Evaluation

Poor aqueous solubility and slow dissolution rate adversely affects bioavailability of pioglitazone hydrochloride. This study was undertaken to improve dissolution and bioavailability of pioglitazone hydrochloride through preparation of stable solid dispersions by melting and solvent evaporation method using Solutol HS 15. Solubility of pioglitazone hydrochloride was enhanced by 9 to 49 fold as the drug-carrier ratio was increased in solid dispersions as compared to pure drug. Furthermore, compared to pure drug or physical mixture, solid dispersions significantly improved the dissolution rate and the extent of drug release. Solid dispersions at 1:7 drug:solutol HS 15 weight ratio showed complete and rapid drug release within 15 min at pH 1.2. The Fourier-transform infrared spectrum revealed the chemical compatibility with solutol HS 15. Differential scanning calorimetry and X-ray powder diffraction pattern revealed a change in crystallinity to amorphous state that supported the enhancement of solubility of pioglitazone hydrochloride with Solutol HS 15. In vivo test showed that Solutol HS 15-based solid dispersions showed higher AUC0-t and Cmax, which was ~4 times higher than that of pure pioglitazone (p<0.05) implying solid dispersions could be effective in increasing the bioavailability. In conclusion, solid dispersions with Solutol HS 15 prepared using solvent evaporation method appeared to be a promising technique to improve the dissolution, bioavailability and stability of pioglitazone hydrochloride.

[1]  Z. Ahmad,et al.  Improvement of solubility, dissolution and stability profile of artemether solid dispersions and self emulsified solid dispersions by solvent evaporation method , 2018, Pharmaceutical development and technology.

[2]  Shrawan Baghel,et al.  Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs. , 2016, Journal of pharmaceutical sciences.

[3]  Dae-Duk Kim,et al.  Poloxamer-based solid dispersions for oral delivery of docetaxel: Differential effects of F68 and P85 on oral docetaxel bioavailability. , 2016, International journal of pharmaceutics.

[4]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[5]  S. S. Imam,et al.  Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail , 2016, Drug delivery.

[6]  Y. Chowdary,et al.  Formulation and Evaluation of Multilayered Tablets of Pioglitazone Hydrochloride and Metformin Hydrochloride , 2014, Journal of pharmaceutics.

[7]  Beom-Jin Lee,et al.  Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  N. Shi,et al.  Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions , 2013 .

[9]  A. Healy,et al.  Surfactants in Pharmaceutical Products and Systems , 2013 .

[10]  V. Suryadevara,et al.  FORMULATION AND OPTIMIZATION OF PIOGLITAZONE SOLID DISPERSIONS PREPARED BY HOT MELT EXTRUSION TECHNIQUE , 2013 .

[11]  V. Jayanthi,et al.  Effect of hydrophilic polymers on isradipine complexation with hydroxypropyl β-cyclodextrin , 2013, Drug development and industrial pharmacy.

[12]  M. Basha,et al.  Soluplus®: A novel polymeric solubilizer for optimization of Carvedilol solid dispersions: Formulation design and effect of method of preparation , 2013 .

[13]  G. Mooter,et al.  The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. , 2012, Drug discovery today. Technologies.

[14]  Hoo-Kyun Choi,et al.  Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol® HS15 as a carrier. , 2012, International journal of pharmaceutics.

[15]  K. Devi,et al.  Preparation and Characterization of Pioglitazone Cyclodextrin Inclusion Complexes , 2011, Journal of young pharmacists : JYP.

[16]  Hyoung-Kyu Lee,et al.  Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation. , 2011, International journal of pharmaceutics.

[17]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[18]  A. Jouyban,et al.  Solubility of pioglitazone hydrochloride in binary mixtures of polyethylene glycol 400 with ethanol, propylene glycol, N-methyl-2-pyrrolidone, and water at 25 degrees C. , 2010, Chemical & pharmaceutical bulletin.

[19]  Neelam Seedher,et al.  Co-solvent solubilization of some poorly-soluble antidiabetic drugs , 2009, Pharmaceutical development and technology.

[20]  P. Bouic,et al.  Permeation of Four Oral Drugs Through Human Intestinal Mucosa , 2009, AAPS PharmSciTech.

[21]  A. A. Elbary,et al.  Formulation and hypoglycemic activity of pioglitazone-cyclodextrin inclusion complexes. , 2008, Drug discoveries & therapeutics.

[22]  S. Baboota,et al.  Formulation development and optimization using nanoemulsion technique: A technical note , 2007, AAPS PharmSciTech.

[23]  I. Gómez-Orellana.  Strategies to improve oral drug bioavailability , 2005, Expert opinion on drug delivery.

[24]  F. Boess,et al.  In vitro investigation on the impact of Solutol HS 15 on the uptake of colchicine into rat hepatocytes. , 2004, International journal of pharmaceutics.

[25]  M. Danhof,et al.  Clinical pharmacokinetics of pioglitazone , 2000 .

[26]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  V. Tantishaiyakul,et al.  Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. , 1996, International journal of pharmaceutics.

[28]  Michael Montagne,et al.  Pharmaceutical Statistics: Practical and Clinical Applications , 1985 .

[29]  J. Patel,et al.  Solubility enhancement using poly(meth)acrylate based solid dispersions , 2015 .

[30]  N. Jahnavi,et al.  Formulation, Evaluation and Characterization of Solid Dispersions of Pioglitazone Hydrochloride , 2013 .

[31]  V. Pokharkar,et al.  Pioglitazone Solid Dispersion System Prepared by Spray Drying Method: In Vitro and In Vivo Evaluation , 2013, PDA Journal of Pharmaceutical Science and Technology.

[32]  R. Shah,et al.  Effect of method of preparation on pioglitazone HCl-β-cyclodextrin inclusion complexes , 2010 .

[33]  D. M. Robinson,et al.  Pioglitazone , 2012, Drugs.

[34]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.